Physician profile
Tayler Robin Ebert
NPI 1710658042
$10,479.13
in general payments reported to CMS, 2019-2025
49 companies · $169 in 2025
The $169 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $551 · 2022: $3,209 · 2023: $2,767 · 2024: $3,784 · 2025: $169.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,719.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $801.18 | 2021-2024 | Xcopri |
| Lundbeck LLC | $792.49 | 2021-2024 | Vyepti, Rexulti |
| Lilly USA, LLC | $698.09 | 2021-2024 | Kisunla, Emgality, Amyvid |
| Abbvie INC. | $691.24 | 2021-2025 | |
| Livanova USA, INC. | $621.91 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Jazz Pharmaceuticals INC. | $569.58 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $395.60 | 2022-2024 | Ingrezza, Ongentys |
| Pfizer INC. | $385.41 | 2023-2024 | |
| Alexion Pharmaceuticals, INC. | $368.46 | 2021-2024 | Ultomiris |
| Ucb, INC. | $345.80 | 2022-2024 | Briviact, Fintepla, Rystiggo |
| Neurelis, INC. | $339.37 | 2021-2024 | Valtoco |
| Harmony Biosciences LLC | $336.29 | 2022-2024 | Wakix |
| Kyowa Kirin, INC. | $317.88 | 2021-2024 | Nourianz |
| Teva Pharmaceuticals USA, INC. | $276.87 | 2021-2024 | Austedo Xr, Austedo |
| Eisai INC. | $265.84 | 2021-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tayler Ebert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.